Skip to main content

01.12.2016 | Research | Ausgabe 1/2016 Open Access

International Journal of Pediatric Endocrinology 1/2016

An audit of the management of childhood-onset growth hormone deficiency during young adulthood in Scotland

International Journal of Pediatric Endocrinology > Ausgabe 1/2016
M. Ahmid, V. Fisher, A. J. Graveling, S. McGeoch, E. McNeil, J. Roach, J. S. Bevan, L. Bath, M. Donaldson, G. Leese, A. Mason, C. G. Perry, N. N. Zammitt, S. F. Ahmed, M. G. Shaikh
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MA and MGS designed, performed data collection, performed the main part of statistical analysis, and wrote the initial draft of the manuscript. SFA conceived of the study and participated in its design and coordination as well as drafting the manuscript. AJG, SM, GL, JSB contributed in data collection and interpretations. All authors made substantial contributions read, edited and approved the final manuscript.



Adolescents with childhood onset growth hormone deficiency (CO-GHD) require re-evaluation of their growth hormone (GH) axis on attainment of final height to determine eligibility for adult GH therapy (rhGH).


Retrospective multicentre review of management of young adults with CO-GHD in four paediatric centres in Scotland during transition.


Medical records of 130 eligible CO-GHD adolescents (78 males), who attained final height between 2005 and 2013 were reviewed. Median (range) age at initial diagnosis of CO-GHD was 10.7 years (0.1–16.4) with a stimulated GH peak of 2.3 μg/l (0.1–6.5). Median age at initiation of rhGH was 10.8 years (0.4–17.0).


Of the 130 CO-GHD adolescents, 74/130(57 %) had GH axis re-evaluation by stimulation tests /IGF-1 measurements. Of those, 61/74 (82 %) remained GHD with 51/74 (69 %) restarting adult rhGH. Predictors of persistent GHD included an organic hypothalamic-pituitary disorder and multiple pituitary hormone deficiencies (MPHD). Of the remaining 56/130 (43 %) patients who were not re-tested, 34/56 (61 %) were transferred to adult services on rhGH without biochemical retesting and 32/34 of these had MPHD. The proportion of adults who were offered rhGH without biochemical re-testing in the four centres ranged between 10 and 50 % of their total cohort.


A substantial proportion of adults with CO-GHD remain GHD, particularly those with MPHD and most opt for treatment with rhGH. Despite clinical guidelines, there is significant variation in the management of CO-GHD in young adulthood across Scotland.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

International Journal of Pediatric Endocrinology 1/2016 Zur Ausgabe

Neu im Fachgebiet Pädiatrie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Pädiatrie und bleiben Sie gut informiert – ganz bequem per eMail.